Form 4: Avidity Biosciences Director Troy Wilson Reports Acquisition of Equity Compensation

Avidity Biosciences, Inc. Director Troy Edward Wilson reported the acquisition of 6,692 restricted stock units and 10,034 stock options on June 10, 2025, as part of his compensation.

Summary

• Director Troy Edward Wilson of Avidity Biosciences, Inc. (RNA) acquired 6,692 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 10, 2025, at a price of $0 per share.
• These RSUs represent a contingent right to receive one share of the Issuer's common stock and will vest in full on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to continuous service.
• Following this transaction, Mr. Wilson beneficially owns 69,425 shares of Common Stock.
• Additionally, Mr. Wilson acquired 10,034 stock options (Right to Buy) on June 10, 2025, with an exercise price of $33.62 per share.
• These stock options will also vest in full on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to continuous service, and have an expiration date of June 9, 2035.
• The filing indicates that the transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The filing reports a standard equity compensation grant to a director, which is a positive sign of alignment between management and shareholder interests, and a routine part of corporate governance.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of long-term shareholders, incentivizing performance and retention.
• The transaction was made under a Rule 10b5-1 plan, indicating a pre-arranged, non-discretionary transaction, which is a common and transparent practice for insider equity compensation.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon the Reporting Person's continuous service to the Issuer through the specified vesting date, meaning the benefits are not guaranteed if service terminates prematurely.

Future Outlook

The equity grants are structured with future vesting dates, indicating an expectation of the director's continued service and commitment to the company's long-term success.

Management Comments

• The filing indicates that the transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

This Form 4 filing represents a routine insider transaction related to director compensation. Equity grants, such as RSUs and stock options, are a standard component of executive and director compensation packages across various industries, designed to align the interests of insiders with those of shareholders.

Comparison to Industry Standards

• The use of restricted stock units and stock options as a form of director compensation is a common practice across publicly traded companies, aligning with general industry standards for incentivizing and retaining key personnel.
• The specific quantities and vesting schedules would typically be benchmarked against peer companies in the biotechnology or pharmaceutical sector, but this document does not provide sufficient detail for such a comparative analysis.

Related Party Transactions

• Grant of equity compensation (6,692 Restricted Stock Units and 10,034 Stock Options) to Director Troy Edward Wilson, which is a standard compensation arrangement between the company and a related party.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: While not directly impacting all employees, such compensation practices can set a precedent for performance-based incentives within the company.

Next Steps

• The acquired restricted stock units and stock options are scheduled to vest in full on the first to occur of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Avidity Biosciences, RNA, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, RSU, Stock Options, Equity Grant, Rule 10b5-1